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Conclusions: Our findings suggest that miR-34a is involved in
docetaxel resistance, which may act by targeting BCL2 and
cyclinD1.
doi:10.1016/j.ejcsup.2010.06.055
O-55 TRANSLATIONAL LANDSCAPE OF EPITHELIAL MESEN-
CHYMAL TRANSITION IN MOLECULAR CLASSES OF INVASIVE
BREAST CANCER
Mohammed A. Aleskandarany a, Andrew R. Green a, Emad A.
Rakha b, Des G. Poweb, Ian O. Ellis a,b. aDivision of Pathology,
University of Nottingham, UK. bDepartment of Pathology, Nottingham
University Hospitals, UK
Epithelial Mesenchymal Transition (EMT), as defined by loss of
epithelial characteristics and gaining a more mesenchymal-like
phenotype, has been largely reported in vivo. However, the actual
occurrence of events defining EMT is rarely fully observed in vivo.
We aimed to explore the translational landscapes of EMT in
breast cancer (BC) with relevance to potential triggering pathways
and BC molecular subtypes. Clustering analysis was performed
on a well-defined clinically annotated series of invasive non-lob-
ular BC (n = 431) prepared as tissue microarray (TMAs). A large
panel of biomarkers including cadherins, TGFb1, PIK3CA, pAkt,
cytokeratins, Erb-family members and hormone receptors, has
been studied. Differential expression of EMT markers was
observed between molecular BC subtypes (Luminal1 and 2,
HER2+, and basal-like (BLBC), where BLBC expressed lower E-
cad, higher P-cad, smooth muscle actin and PIK3CA, relative to
HER2+ BC that expressed highest levels of N-cad, TGFb1 and
PIK3CA. Within luminal tumours subdivisions, expression levels
of N-cad, TGFb1, pAkt and PIK3CA differed considerably. N-cad
contributed to cluster separation more than E-cad (F = 13.14 and
1.68, respectively). Moreover, E-cad/N-cad switch occurred more
frequently in BLBC and HER2+. Significant differences were
observed between these four clusters for breast cancer-specific
and disease-free survivals (p < 0.001).
BLBC and HER2+ BC preferentially displayed EMT/cadherin
switch than luminal BC, explaining their indigenous tendency
for progression. In addition, EMT/cadherin switch programs in
BC appear to occur synergistically with TGFb1 and PIK3/Akt path-
ways activation. These data explain, at translational level, the
varied clinical behaviour of BC molecular classes, thus could help
developing targeted therapies against EMT-associated pathways.
doi:10.1016/j.ejcsup.2010.06.056
O-56 HIGH EXPRESSION OF SPHINGOSINE 1-PHOSPHATE
RECEPTORS, S1P1 AND S1P3, SPHINGOSINE KINASE 1 AND ERK-
1/2 IS ASSOCIATED WITH DEVELOPMENT OF TAMOXIFEN
RESISTANCE IN ER POSITIVE BREAST CANCER PATIENTS
Carol Watson, Jaclyn S. Long, Clare Orange, Claire L. Tannahill,
Elizabeth Mallon, Liane M. McGlynn, Susan Pyne, Nigel J. Pyne,
Joanne Edwards. University of Glasgow, UK
Cell line studies demonstrate that sphingosine kinase 1 (SK1)
and extracellular signal regulated kinase 1/2 (ERK-1/2) interact in
an oestrogen receptor (ER) dependent manner to influence
breast cancer cell growth and migration. A cohort of 304 ER posi-
tive breast cancer patients, were utilised to investigate the prog-
nostic significance of SK1, sphingosine 1-phosphate receptors 1,
2 and 3 (S1P1, S1P2 an S1P3) and ERK-1/2 expression. Expression
levels of SK1, S1P1, S1P2 and S1P3 were established by immuno-
histochemistry. Cytoplasmic and nuclear SK1 expression was
associated with shorter time to recurrence on tamoxifen (recur-
rence time) (p = 0.022 and p = 0.016, respectively) and high mem-
brane S1P1 expression was also associated with shorter time to
recurrence (p = 0.008). High cytoplasmic S1P1 and S1P3 expres-
sion were associated with shorter disease specific survival
(p = 0.036 and p = 0.019). Those patients with tumours that
expressed high levels of both cytoplasmic SK1 and ERK-1/2
had significantly shorter recurrence time than those that
expressed low levels of cytoplasmic SK1 and cytoplasmic ERK-
1/2 (p = 0.00008), with a difference in recurrence time of
10.5 years. Similarly, high cytoplasmic S1P1 and cytoplasmic
ERK-1/2 expression (p = 0.004) and high cytoplasmic S1P3 expres-
sion and cytoplasmic ERK-1/2 expression (p = 0.004), were associ-
ated with shorter recurrence time. These results support a
model in which the interaction between SK1, S1P1 and/or S1P3
and ERK-1/2 might drive breast cancer progression and this
therefore warrants further investigation.
doi:10.1016/j.ejcsup.2010.06.057
O-57 SCREEN DETECTED DCIS IN THE EAST MIDLANDS REGION:
COMPARISONS IN TREATMENT AND OUTCOME OVER TIME
(1988–2003)
J.A. Reed a, A. Murphy a, G. Comerie a, D.M. Sibbering b. aEast
Midlands Quality Assurance (QA) Reference Centre, Nottingham,
UK. bRoyal Derby Hospital, Derby, UK
A retrospective study was carried out comparing three cohorts
of consecutive patients diagnosed with DCIS via the NHSBSP in
the East Midlands region. Diagnostic, treatment and follow-up
outcome data was collected by individual patient case notes
review, and where necessary by contacting general practitioners.
Kaplan–Meier survival analysis was performed using SPSS.
Histological excision margins were increasingly clear over
time 88% (88/93), 91.5% (94/97) and 98% (00/03). The overall local
recurrence free survival rate was identical for both earlier periods
with 92% at 5 years but improved to 96.1% over 2000/03. 40–56% of
all local recurrences were invasive; 13/23 (88/93), 14/26 (94/97),
and 8/21 (00/03). Use of tamoxifen within the three cohorts was
similar (44–46%) and made no significant difference to rates of
local or contralateral recurrence free survival. Significant differ-
ences in local recurrence rates by operation type were observed
(see Table 1).
Conclusion: Local recurrence rates after breast conserving sur-
gery for screen detected DCIS have reduced over time. This is
likely to be related to higher rates of non-operative diagnosis,
combined with improved histological assessment (grading and
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margin status), more aggressive surgery and increasing use of
radiotherapy.
doi:10.1016/j.ejcsup.2010.06.058
O-58 FACTORS INFLUENCING LOCAL CONTROL IN PATIENTS
UNDERGOING BREAST CONSERVATION SURGERY FOR DUCTAL
CARCINOMA IN SITU
J. Mathewa, R. Karia a, N. Warrich a, D. Morgan b, A. Lee c, I. Ellis c, J.
Robertson a, A. Bello a. aDivision of Breast Surgery, Nottingham
University Hospitals, Nottingham, UK. bDepartment of Oncology,
Nottingham University Hospitals, Nottingham, UK. cDepartment of
Pathology, Nottingham University Hospitals, Nottingham, UK
Background: The aim of our study was to assess various
risk factors for local recurrence (LR) in patients undergoing
breast conservation surgery (BCS) for ductal carcinoma
in situ (DCIS).
Materials and methods: Retrospective case note review
between January 1975 and June 2008. In our hospital a margin
of P10 mm is considered acceptable. Patients were divided into
three groups based on pathological margin (<5 mm, 5–9 mm
and P10 mm). Cox regression model for multivariate analysis
of local recurrence was used with variables with significant P
values (<0.05) in the univariate analysis carried out using SPSS
version 16.
Results: Overall 239 women had BCS for DCIS during the above
period. The median age was 59 years (40–86) and the median fol-
low-up was 76 months (1–308). Pathological findings included
median size of 11 mm (1–50), 75 cases with comedo necrosis
and 5 patients with microinvasion (<1 mm). Overall 193 patients
had grades recorded (44 low grade, 54 intermediate grade and
95 high grade).
Overall LR rate was 17% (40/239), of which 65% (26/40) were
invasive recurrences. Thirty-one patients were 6 to 50 years
and 32% (10/31) developed LR compared to 14% (30/208) in
those above 50 years (P = 0.018). Forty-three percent of patients
(6/14) with <5 mm margin developed LR compared to 12% (3/
25) with 5–9 mm margin and 14% (27/188) with P10 mm mar-
gin. Four out of 12 patients with unknown margin status
developed LR. The LR rate in patients with <5 mm (6/14) mar-
gin was significantly higher compared to those with P5 mm
(30/213) margin (P value < 0.012). Three out of 5 patients with
microinvasion developed LR and it was statistically significant
(P = 0.034) compared to those without microinvasion. On multi-
variate analysis age 650 years, <5 mm pathological margin and
microinvasion were independent poor prognostic factors for
local recurrence.
Conclusion: Our study shows that younger age (650 years), a
clear margin <5 mm and associated microinvasion are poor prog-
nostic factors for LR in patients undergoing breast conservation
surgery for DCIS.
doi:10.1016/j.ejcsup.2010.06.059
O-59 SINGLE CENTRE EXPERIENCE OF 500 PATIENTS WITH
INTRA-OPERATIVE RT-PCR BREAST SENTINEL NODE ANALYSIS
V. Brown, R. Cutress, T. Simoes, A. Agrawal, M. Wise, I. Cree, C.
Yiangou. Portsmouth Breast Cancer Centre, Queen Alexandra Hospital,
Portsmouth, UK
Introduction: Tumour specific mRNA markers detected by real
time reverse transcriptase-polymerase chain reaction (RT-PCR)
have been used to detect breast cancer metastases in sentinel
lymph nodes. We present our experience of 500 consecutive cases
in a single centre.
Methods: All clinically and radiologically node negative
patients who underwent sentinel node biopsy (SLNB) were
included in the study over a 24-month period. SLNB was per-
formed according to New Start guidelines. Intraoperative anal-
ysis was performed on alternate slices at 2 mm intervals,
with the remaining slices sent for standard histological anal-
ysis. The GeneSearch assay (Veridex LLC, Warren, NJ) was
used to detect the expression of mammaglobin (MG) and
cytokeratin 19 (CK). Patients were considered SLNB positive
if one or more sentinel lymph nodes were positive for either
MG or CK.
Results: Sentinel lymph nodes (912) were analysed with an
average of 1.8 nodes per patient. The cohort was representative
Table 1
Time period 1988–1993 (n. 300) 1994–1997 (n. 319) 2000–2003 (n. 547)
Non-operative diagnosis 59 (20%) 142 (45%) 439 (80%)
Treatment
Mastectomy 134 (45%) 127 (40%) 205 (37%)
Wide local excision 123 (41%) 141 (44%) 294 (54%)
Diagnostic excision alone 43 (14%) 51 (16%) 48 (9%)
Radiotherapy (post conservation) 24 (15%) 25 (13%) 186 (54%)
Tamoxifen 139 (46%) 149 (47%) 240 (44%)
5 year LRR
Mastectomy 2 (1.5%) 3 (2.5%) 1 (0.5%)
Wide local excision 12 (10%) 17 (12%) 19 (6.5%)
Diagnostic excision alone 9 (22%) 6 (12%) 1 (2%)
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